Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | MYD88 | Q99836 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148132 | 0.99 | KMO (0.49) | KMOMAPTRAB9ARECQLMEN1 | |
| SCHEMBL10148140 | 0.94 | KMO (0.49) | KMOMAPTRAB9ARECQLMEN1 | |
| SCHEMBL10148139 | 0.93 | KMO (0.48) | KMOMAPTRAB9ARECQLMEN1 | |
| SCHEMBL10148137 | 0.92 | KMO (0.47) | KMOMAPTRAB9ARECQLMEN1 | |
| SCHEMBL10148167 | 0.86 | KMO (0.54) | KMOMAPTRAB9ARECQLMEN1 | |
| SCHEMBL10148168 | 0.86 | KMO (0.54) | KMOMAPTRAB9ARECQLMEN1 | |
| SCHEMBL10148131 | 0.85 | KMO (0.53) | KMOMAPTRAB9ARECQLMEN1 | |
| SCHEMBL424436 | 0.84 | KMO (0.57) | KMOMAPTRAB9ARECQLMEN1 | |
| SCHEMBL10148142 | 0.83 | KMO (0.51) | KMOMAPTRAB9ARECQLMEN1 | |
| SCHEMBL424462 | 0.83 | KMO (0.58) | KMOMAPTRAB9ARECQLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710237-B2 | Small molecule inhibitors of kynurenine-3-monooxygenase | THE J. DAVID GLADSTONE INSTITUTE (US) | 2014-04-29 | — | — | US | disclosed |
| US-20120022052-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022052-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | KMO, KYNU, TDO2 | KMO 1/4885MAPT 898/4885RAB9A 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.